2022 Networking Pharmaceutical manufacturing 
European Pharmaceutical Review
APRIL 18, 2023
billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.
pharmaphorum
JANUARY 24, 2023
Its report points to some positive developments under the umbrella of the UK’s Life Sciences Vision (LSV) programme, including £20 million in grant funding for medicines manufacturing investments in the 2020 single-year ending review, and the £60 million Life Sciences Innovative Manufacturing Fund (LSIMF) announced in March 2022.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 28, 2022
FDI experts at Investment Monitor have highlighted the following list of factors as most important to life sciences companies considering a greenfield investment in 2022: labour, education, industry clusters, domestic market, infrastructure, business environment, costs and quality of life. appeared first on Pharmaceutical Technology.
European Pharmaceutical Review
OCTOBER 24, 2022
Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.
European Pharmaceutical Review
JULY 25, 2022
Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. Criminal networks are penetrating established digital and ecommerce channels, benefitting from their trusted authenticity and authority to distribute fake products to unsuspecting patients.
PM360
OCTOBER 25, 2023
Combination Therapy in Oncology Combination therapies comprising two or more therapeutic agents have become a cornerstone of oncology management and are increasingly a development focus for the pharmaceutical industry. JAMA Network Open 5 , no. 3 (2022): e222265. Between May 1, 2016, and May 31, 2021, 42% of all U.S. 2022.2265.
Pharma Marketing Network
JANUARY 18, 2023
Bob is a life sciences and technology marketing leader with more than 25 years of experience working directly for pharmaceutical manufacturers (Merck, AstraZeneca, and Shire) and for technology companies that serve the industry (Appature, IQVIA, and Sparta). The post Bob Harrell appeared first on Pharma Marketing Network.
Expert insights. Personalized for you.
98 
Let's personalize your content